2026-06-25

Technology Platform | AlfaBodY Intelligent Molecular Design Platform Powers New Drug R&D: Deliver PCC+ in 8 Months and Conquer Hard-to-Drug Targets

2026-06-10

Tech Platform | AlfaDAX Platform Iteratively Optimizes Nanobodies, Delivering a 10-Fold Affinity Improvement in 1.5 Months

2026-06-03

Technology Platform | AI-Enabled Antibody Molecular Engineering: Iterative Optimization of the AlfaDAX Platform Breaks Through Traditional R&D Bottlenecks

2026-05-20

Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

2026-03-27

Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

2026-03-26

Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

2026-03-09

Great Bay Bio’s CHO-K1 Catalog Medium AlfaMedX- K1 (Growth Factor–Free) Achieves FDA DMF Filing

2025-11-14

Kingsley Leung, Chairman of Great Bay Bio, Awarded the FHKI X OCBC Hong Kong Innopreneur Awards 2025, Recognizing Outstanding Innovation

2025-11-11

Great Bay Bio and Taron Form Strategic Partnership to Advance HK Biopharmaceutical Innovation

2025-06-20

Great Bay Bio and Eureka Therapeutics Partner to Develop AI-Powered Antibody Discovery Model